According to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine, diabetes management technology is just beginning and can have a positive impact on the daily lives of diabetes patients.
According to Eda Cengiz, MD, MHS, FAAP, associate professor of pediatrics at Yale School of Medicine, diabetes management technology is just beginning and can have a positive impact on the daily lives of diabetes patients.
Transcript (slightly modified)
What’s your outlook on the future of diabetes management technology, including artificial pancreas systems?
This is the beginning of a digital revolution, a diabetes technology revolution, and I think we should be open to this.
When we have 70% to 80% of our patients in poor control, we cannot afford to wait. It’s our duty as clinicians to look for alternative tools to improve diabetes care. No matter what the reason is, people say it’s the compliance or some other issues that result in poor control, it’s our duty to find and implement new tools that our patients will benefit from.
I think a lot of people will like the system but they have to be realistic. This is not the perfect, full, automated, artificial pancreas system. They have to be patient and they have to learn the system and then once they get used to it, once we incorporate new technology and advances into the system, I think they are going to like it better and better. They are going to sleep better, they are going to feel better, they can exercise without any worries, and hopefully it will be the perfect system that will improve our outcomes until we have a cure.
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More